ARTICLE SUMMARY:
Seemingly on the cusp of a regenerative medicine resurgence, leading US biomaterials scientist-entrepreneurs talk with MedTech Strategist about advances in both the regulatory framework and science of cell therapy-based approaches to treating intractable musculoskeletal conditions. The first of a three-part series focuses on Cornell University’s Lawrence Bonassar’s breakthroughs in materials processing, which aim to enable scaling up manufacturing of regenerative products.
Regenerative medicine and cellular therapy are hot buzzwords in the life sciences start-up world these days. Last year, that designation likely went to artificial intelligence, but that term’s glow, while certainly continuing, seems to be leveling off for young companies seeking public attention and funding, perhaps because its use is saturated and the field of healthcare AI is getting crowded.
